End-Stage Renal Disease Market Size in the 7MM is Estimated to Exceed USD 249.0 Billion by 2035

The end-stage renal disease market reached a value of USD 84.2 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 249.0 Billion by 2035, exhibiting a growth rate (CAGR) of 10.39% during 2025-2035.

In 2025, the End-Stage Renal Disease (ESRD) market is undergoing transformation due to the changing global dynamics of chronic kidney disease burden, treatment options, and awareness surrounding early diagnosis and kidney care. Also referred to as kidney failure, ESRD is the last stage of chronic kidney disease where kidneys are unable to function with reasonable efficiency, leading to the need for life-sustaining dialysis or kidney transplants. Increasing life expectancy combined with the population suffering from diabetes, hypertension, and other lifestyle-related diseases continues to drive the market.

The ESRD market encompasses all the necessary consumables, medical devices, services, and medications pertaining to a patient who is 85% to 90% kidney functionally disabled. The market includes diabetes care, education, and management. The market is primarily driven by the growing prevalence of diabetes which continues to be a leading contributor for kidney failure around the world. Health reports suggest that Chronic Kidney Disease (CKD) poses a major global health issue and is among the top fifteen causes of death worldwide. CKD is estimated to increase the prevalence rate of End-Stage Renal Disease (ESRD) significantly, with millions suffering every year.

Request for a sample of this report: https://www.imarcgroup.com/end-stage-renal-disease-market/requestsample

Dialysis is the most prevalent treatment for ESRD and will persist up to 2025. Hemodialysis and peritoneal dialysis treatment modalities are employed according to the condition of the patient and the level of accessibility. Newer possibilities in the market are developing as a result of technological advances in the dialysis machines, home dialysis units, and wearable artificial kidneys. Firms are concentrating on the creation of portable and uncomplicated machines that are easy to use with the aim of improving ESRD patients' quality of life and reducing reliance on in-center dialysis. Specifically, home dialysis is increasing because of its convenient application and economic savings.

Although kidney transplantation is currently the most powerful long-term therapy for ESRD, it is currently short of a donor source. In 2025, scientists and drug corporations are placing emphasis on bettering post transplant management by advanced immunosuppressive therapy and techniques for better organ preservation. These advances are looking to increase the survival time of transplant recipients and reduce the likelihood of organ rejection.

One of the developing trends within the ESRD market is the increasing focus on delivering early intervention and chronic disease management. Governments and healthcare providers are establishing new screening programs and public health initiatives in an attempt to catch kidney disease at its earlier stages. This type of proactive care not only postpones transition to ESRD but is also less expensive with regard to offering financial and healthcare support.

Digital ESRD technologies are becoming more popular alongside telemedicine platforms, remote patient monitoring tools, and AI-powered diagnostic solutions which are tailoring treatments, increasing disease monitoring, and improving patient interventions. These tools assist healthcare providers in enhancing decision-making and patient outcomes.

Ask the Analyst for Customization and Get Full Insights with TOC: https://www.imarcgroup.com/request?type=report&id=7141&flag=E

This report also provides a detailed analysis of the current end-stage renal disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Competitive Landscape With Key Players:

The competitive landscape of the end-stage renal disease market has been studied in the report with the detailed profiles of the key players operating in the market.

Boehringer Ingelheim Pharmaceuticals, Inc.
Aronora, Inc.

IMARC Group Offers Other Reports:

Kidney Transplant Rejection Marketᅠ
https://www.imarcgroup.com/kidney-transplant-rejection-market

Anemia in Chronic Kidney Disease Marketᅠ
https://www.imarcgroup.com/anemia-in-chronic-kidney-disease-market

Acute Renal Failure Marketᅠhttps://www.imarcgroup.com/acute-kidney-injury-market

Polycystic Kidney Disease Marketᅠhttps://www.imarcgroup.com/polycystic-kidney-disease-market

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.